This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment


Litvinenko, I. V., Vorob'ev, S. V., Lobzin, V. Yu, Lupanov, I. A.


Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 113, No.: 9, Pages.: 29-35

Year of Publication



An aim of the study was to investigate the efficacy and safety of noojerone (memantine) in patients with cognitive impairment comorbid to brain ischemia, stages II-III. The main group (30 patients, aged 64-86 years) was treated with noojerone in addition to standard therapy according to dosage scheme during 6 months. The control group (15 patients, aged 61-78 years) received standard therapy only. Patients underwent somatic and neurological examinations, along with neuropsychological testing (MMSE, FAB and other tests). The use of noojerone in complex treatment decreased cognitive impairment in the main group compared to the control one. The most distinct changes were noted on MMSE. Statistically significant changes appeared during the 12th week. The maximal effect was observed when the drug was applied during 6 months. Noojerone was well-tolerated by the patients. ;


aged, aged, 80 and over, brain ischemia, cognition disorders, complications, drug therapy, epidemiology, etiology, excitatory amino acid antagonists, female, humans, male, memantine, therapeutic use

Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime